Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11287246 | 0.82 | HDAC4 (0.61) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL467546 | 0.80 | HDAC4 (0.59) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL11336506 | 0.78 | BRD4 (0.47) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL3739983 | 0.78 | HDAC4 (0.57) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL10882007 | 0.78 | BRD4 (0.63) | HDAC4HDAC7HDAC5BRD4CES2 | |
| Hydrochloric Acid SCHEMBL933980 | 0.78 | HDAC4 (0.57) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL8127120 | 0.78 | CYP1A2 (0.47) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL5684986 | 0.78 | HDAC3 (0.57) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL11836466 | 0.78 | BRD4 (0.47) | HDAC4HDAC7HDAC5BRD4CES2 | |
| SCHEMBL237104 | 0.77 | TDP1 (0.56) | HDAC4HDAC7HDAC5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088800-A1 | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2011008475-A1 | OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES | ALLERGAN, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-1017672-B1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6127414-A | NPY antagonists | ASTRA AKTIEBOLAG (SE) | 2000-10-03 | — | — | US | disclosed |
| EP-1017672-A1 | NEW NPY ANTAGONISTS | AstraZeneca AB (SE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015498-A1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 1999-04-01 | — | — | WO | disclosed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-4536346-A | TREATMENT OF ATHEROSCLEROSIS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| US-4489094-A | Arylalkylaminobenzoic acids | AMERICAN CYANAMID COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0124791-A1 | Aralkanamidophenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088800-A1 | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS | S1PR3, S1PR5, S1PR1 | HDAC4 2817/4885HDAC7 3008/4885HDAC5 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.